Search Result

Results for "

α-Amylase Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (49) Apoptosis (1) Bacterial (1) Cholinesterase (ChE) (1) COX (1) Dipeptidyl Peptidase (2) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (1) Fungal (1) GLUT (2) Glycosidase (36) HDAC (1) NF-κB (2) P-glycoprotein (1) Phosphatase (2) PPAR (1) Tyrosinase (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Inflammation/Immunology (5) Metabolic Disease (55) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135530

Chinese gallotannin	Amylases	Metabolic Disease
Chinese gallotannin is a non-specific promiscuous *α-amylase* inhibitor with a K_i of 0.82 μg/mL for human salivary α-amylase. Chinese gallotannin can be used for the research of diabetes .

HY-146752

α-Amylase-IN-1	Amylases	Others
α-Amylase-IN-1 is a potent *α-amylase* inhibitor with an IC_{50 of 4.46 μM .}

HY-162673

α-Amylase/α-Glucosidase-IN-16	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of *α-amylase* and α-Glucosidase with IC₅₀ values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .

HY-N12263

3,5,6,7,8,4'-Hexamethoxyflavone	Amylases	Metabolic Disease
3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of *α-Amylase* with the inhibitory activity of 28.3% at 500 μM .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Amylases	Metabolic Disease
Quercetin 3-(6″-caffeoylsophoroside) is an orally active *α-amylase* inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-157537

α-Amylase-IN-5	Amylases	Metabolic Disease
α-Amylase-IN-5 (compound 3a) is a *α-amylase* inhibitor, with an IC₅₀ of 18.8 mM .

HY-146225

α-Amylase/α-Glucosidase-IN-2	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent *α-amylase* and α-glucosidase dual inhibitor with IC₅₀ values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .

HY-161782

α-Amylase-IN-7	Amylases	Metabolic Disease
α-Amylase-IN-7 (Compound 6e) is an inhibitor for *α-Amylase* with an IC₅₀ of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent .

HY-133718

Acarviosin (S)-Acarviosin	Amylases	Others
Acarviosin, a pseudodisaccharide moiety, is a part of the potent inhibitor of α-amylase .

HY-161944

α-Amylase-IN-8	Amylases	Metabolic Disease
α-Amylase-IN-8 (compound 44) is an *α-amylase* inhibitor (IC₅₀=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes .

HY-170548

α-Amylase-IN-10	Amylases	Metabolic Disease
α-Amylase-IN-10 (Compound 15n) is an inhibitor for *α-Amylase* with an IC₅₀ of 5.00 µM. α-Amylase-IN-10 can be used for research of type 2 diabetes mellitus .

HY-168598

α-Amylase-IN-9	Amylases	Metabolic Disease
α-Amylase-IN-9 (Compound 1i) is an inhibitor of *α-Amylase* with an IC₅₀ value of 14.64 μM, which can be used in diabetes research .

HY-168961

α-Amylase/α-Glucosidase-IN-18	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is the inhibitor for *α-Amylase* and α-Glucosidase with IC₅₀ of 49.17 nM and 10.71 nM. α-Amylase/α-Glucosidase-IN-18 can be used in research of type 2 diabetes mellitus .

HY-162634

α-Amylase/α-Glucosidase-IN-15	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and *α-amylase, with the IC₅₀*s of 21 μM and 61 μM, respectively .

HY-149008

α-Amylase-IN-3	Amylases	Metabolic Disease Cancer
α-Amylase-IN-3 (Compound 4) is a none-competitive type of *α-Amylase* inhibitor with an IC₅₀ value of 18.04 μM, which also has radical scavenging activities (DPPH and ABTS) with IC₅₀ values of 16.04 μM (DPPH) and 16.99 μM (ABTS), respectively. α-Amylase-IN-3 has good protein–ligand interactions profile against α-Amylase. α-Amylase-IN-3 may have pharmacological activities such as anti-oxidative, anti-inflammatory inhibitory, which is helpful for the development of diabetes and oxidative stress associated disease .

HY-147711

α-Amylase/α-Glucosidase-IN-1	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent *α-amylase/α-glucosidase* inhibitor with IC₅₀s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .

HY-161355

α-Amylase/α-Glucosidase-IN-9	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both *α-amylase* (IC₅₀ = 16.4 μM) and α-glucosidase (IC₅₀ = 31.6 μM) enzymes .

HY-162635

α-Amylase/α-Glucosidase-IN-14	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of *α-amylase* and α-glucosidase, with the IC₅₀s of 45.53 μM and 27.73 μM, respectively .

HY-149557

α-Amylase/α-Glucosidase-IN-5	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-156380

α-Amylase/α-Glucosidase-IN-6	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .

HY-155241

α-Amylase/α-Glucosidase-IN-4	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-168495

α-Amylase-IN-12	Amylases Glycosidase	Metabolic Disease
α-Amylase-IN-12 (Compound 5e) is an *α-amylase* inhibitor (IC₅₀: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC₅₀ of 9.40 mM against α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase-IN-12 can be used for the research of diabetes .

HY-132179

Fucoidan 2 Publications Verification	Glycosidase	Cardiovascular Disease Metabolic Disease Cancer
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .

HY-172211

α-Amylase/α-Glucosidase-IN-17	Amylases Glycosidase	Metabolic Disease Cancer
α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of *α-amylase* and α-glucosidase, with IC₅₀ values of 14.61 μM and 25.38 μM, respectively. α-Amylase/α-Glucosidase-IN-17 has certain inhibitory activity against A549 cancer cells. α-Amylase/α-Glucosidase-IN-17 has anti-tumor and anti-diabetic effects .

HY-162390

α-Amylase/α-Glucosidase-IN-11	Amylases Glycosidase	Endocrinology
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits *α-amylase* (IC₅₀ = 30.39 μM) and α-glucosidase (IC₅₀ = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .

HY-162169

α-Amylase/α-Glucosidase-IN-8	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of *α-amylase* and α-glucosidase, with IC₅₀s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC₅₀ = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .

HY-162036

α-Amylase/α-Glucosidase-IN-7	Glycosidase Amylases Cholinesterase (ChE)	Neurological Disease Metabolic Disease
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive α-glucosidase and *α-amylase* enzyme inhibitor with IC₅₀ values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC₅₀ values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .

HY-163439

α-Amylase/α-Glucosidase-IN-12	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC₅₀ of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research .

HY-170796

α-Amylase-IN-11	Amylases	Metabolic Disease
α-Amylase-IN-11 (compound C5f) is an *α-Amylase* inhibitor (IC₅₀=0.56 μM) that can reduce the sugar level in vivo. α-Amylase-IN-11 has a moderate inhibitory effect on α-glucosidase (α-glucosidase), with IC₅₀=11.03 μM. α-Amylase-IN-11 can significantly reduce the glucose concentration in a mouse model and has the potential for use in diabetes research .

HY-N1425

Tiliroside	Others	Metabolic Disease
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-W727627

5-O-Coumaroylquinic acid	Amylases	Metabolic Disease
5-O-Coumaroylquinic acid is a potent, reversible, non-competitive *α-amylase* inhibitor with an IC₅₀ value of 69.39 μM. 5-O-Coumaroylquinic acid can be used in diabetes research .

HY-N10413

Diphlorethohydroxycarmalol	Glycosidase	Metabolic Disease
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and *α-amylase* inhibitor with IC₅₀s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .

HY-162373

α-Amylase/α-Glucosidase-IN-10	Amylases Glycosidase P-glycoprotein	Metabolic Disease
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC₅₀: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .

HY-N14506

Gibbestatin B	Amylases	Others
Gibbestatin B inhibits the expression of α-amylase induced by gibberellin in De-embryoned rice and barley (IC₅₀ is 25-50 ppm), and has no anti-bacterial, anti-yeast and anti-fungal effects at 100 ppm .

HY-N7729

Sekikaic acid	Amylases Glycosidase	Metabolic Disease
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-143268

HPA-IN-1	Amylases Glycosidase	Metabolic Disease
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .

HY-W005598

2-Hydroxyquinoline	Glycosidase	Metabolic Disease
2-Hydroxyquinoline is a potent α-glucosidase inhibitor with IC₅₀ values of 64.4, 130.5 µg/mL for α-glucosidase and α-amylase, respectively. 2-Hydroxyquinoline has the potential for the research of diabetes .

HY-143269

HPA-IN-2	Amylases Glycosidase	Metabolic Disease
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-W112651

2,4,6-Triphenylaniline	Glycosidase Amylases	Metabolic Disease
2,4,6-Triphenylaniline has anti-diabetic activity and can be encapsulated in nano-emulsions (NE) to enhance stability and permeability. The NE loaded with 2,4,6-Triphenylaniline inhibits α-glucosidase and *α-amylase* .

HY-N1425R

Tiliroside (Standard)	Others	Metabolic Disease
Tiliroside (Standard) is the analytical standard of Tiliroside. This product is intended for research and analytical applications. Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of *α-amylase* with a K_i value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-169737

Inulobiose	Glycosidase Amylases	Metabolic Disease
Inulobiose is a difructan disaccharide that can be isolated from Pistacia vera L.. Inulobiose inhibits α-glycosidase and *α-amylase* activities with IC₅₀s of 1.87 and 40.72 mg/mL, respectively. Inulobiose can be used for the research of diabetes and glomerular filtration rate testing .

HY-N0668R

Rubusoside (Standard)	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits *NF-κB and α-amylase* (α-amylase) .**

HY-168944

ABCB1-IN-4	Amylases Glycosidase	Metabolic Disease
ABCB1-IN-4 (Compound C6z) is an orally active and potent dual *α-amylase* and α-glucosidase inhibitor with IC₅₀ values of 1.63 μM and 0.14 μM, respectively. ABCB1-IN-4 is promising for research of diabetes .

HY-149313

α‑Amylase-IN-1	Amylases	Metabolic Disease
α Amylase-IN-1 (Compound 11) is an *α-Amylase* inhibitor with an IC₅₀ value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC₅₀ value of 53.49 μM for scavenging DPPH free radicals. IC₅₀ can be used in the study of diabetes and oxidative stress-related diseases.

HY-161429

Antidiabetic agent 5	Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and *α-amylase* with IC₅₀ values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-Y0598

trans-Chalcone	Fatty Acid Synthase (FASN) Apoptosis Fungal	Inflammation/Immunology Cancer
trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and *α-amylase* inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity .

HY-N12688

2,3-Dihydrocalodenin B	Glycosidase Amylases	Metabolic Disease
2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against α-glucosidase and *α-amylase, with IC₅₀* values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, *α-amylase, and α-glucosidase* with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-161469

α-Amylase/α-Glucosidase-IN-13	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of *α-Amylase/α-Glucosidase* that can be used for diabetes research .

Cat. No.	Product Name	Target	Research Area

HY-P2055

A-57696	Peptides	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

α-Amylase Inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products